Young smiling boy
gray picture on left of breadcrumbs
 > Home  > Medical  > conclusions  > h

References: H

  • Habib, K. E., K. P. Weld, K. C. Rice, J. Pushkas, M. Champoux, S. Listwak, E. L. Webster, A. J. Atkinson, J. Schulkin, C. Contoreggi, G. P. Chrousos, S. M. McCann, S. J. Suomi, J. D. Higley, and P. W. Gold. 2000. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA 97:6079-6084.
  • Hagerman, R. J. 1984. Pediatric assessment of the learning disabled child. J. Dev. Behav. Pediatr. 5:274-284.
  • ---. 1987. Fragile X syndrome. Curr. Probl. Pediatr. 11:627-674.
  • ---. 1995. Growth and development. In W. W. Hay, J. R. Groothuis, A. R. Hayward, and M. J. Levin (eds.), Current pediatric diagnosis and treatment, 12th ed. Hartford, Conn.: Appleton & Lange, pp. 65-84.
  • ---. 1996. Medical follow-up and pharmacotherapy. In R. J. Hagerman and A. Cronister (eds.), Fragile X syndrome: Diagnosis, treatment, and research, 2d ed. Baltimore: Johns Hopkins Univ. Press, pp. 283-331.
  • ---. 1997. Fragile X: Treatment of hyperactivity [letter]. Pediatrics 99:753.
  • ---. 1999a. Fragile X syndrome. In: Neurodevelopmental Disorders: Diagnosis and Treatment. New York: Oxford University Press, pp. 61-132.
  • ---. 1999b. Psychopharmacological interventions in fragile X syndrome, fetal alcohol syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velocardiofacial syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 5:305-313.
  • Hagerman, R. J., A. W. Jackson, A. Levitas, B. Rimland, and M. Braden. 1986. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am. J. Med. Genet. 23:241-262.
  • Hagerman, R. J., D. Altshul-Stark, and P. McBogg. 1987. Recurrent otitis media in boys with the fragile X syndrome. Am. J. Dis. Child. 141:184-187.
  • Hagerman, R. J., M. Murphy, and M. Wittenberger. 1988. A controlled trial of stimulant medication in children with fragile X syndrome. Am. J. Med. Genet. 30:377-392.
  • Hagerman, R. J., M. J. Fulton, A. Leaman, J. Riddle, K. Hagerman, and W. Sobesky. 1994. A survey of fluoxetine therapy in fragile X syndrome. Dev. Brain Dysfunct. 7:155-164.
  • Hagerman, R. J., J. E. Riddle, L. S. Roberts, K. Brease, and M. Fulton. 1995. A survey of the efficacy of clonidine in fragile X syndrome. Dev. Brain Dysfunct. 8:336-344.
  • Hagerman, R. J., J. D. Bregman, and E. Tirosh. 1998. Clonidine. In S. Reiss and M. G. Aman (eds.), Psychotropic medications and developmental disabilities: The international consensus handbook. Columbus, Ohio: OSU Nisonger Center (distributed by the American Association on Mental Retardation), pp. 259-269.
  • Hagerman, R. J., J. Hills, S. Scharfenaker, and H. Lewis. 1999. Fragile X syndrome and selective mutism. Am. J. Med. Genet. 83:313-317.
  • Hagerman, R. J., L. J. Miller, J. McGrath-Clarke, K. Riley, E. Goldson, S. W. Harris, J. Simon, K. Church, J. Bonnell, and D. McIntosh. 2001. The influence of stimulants on electrodermal studies in fragile X syndrome. Microsc. Res. Tech. In press.
  • Hagino, O. R., E. B. Weller, R. A. Weller, D. Washing, M. A. Fristad, and S. A. Kontras. 1995. Untoward effects of lithium treatment in children aged four through six years. J. Am. Acad. Child. Adolesc. Psychiatry 34:1584-1590.
  • Hampson, R. E., G. Rogers, G. Lynch, and S. A. Deadwyler. 1998. Facilitative effects of the ampakine CX516 on short term memory in rats: Enhancement of delayed-nonmatch-to-sample performance. J. Neurosci. 18:2740-2747.
  • Handen, B. L., A. M. Breaux, A. Gosling, D. L. Ploof, and H. Feldman. 1990. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder. Pediatrics 86:922-930.
  • Handen, B. L., H. Feldman, A. Gosling, A. M. Breaux, and S. McAuliffe. 1991. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 30:241-245.
  • Handen, B. L., A. M. Breaux, J. Janosky, S. McAuliffe, H. Feldman, and A. Gosling. 1992. Effects and noneffects of methylphenidate in children with mental retardation and ADHD. J. Am. Acad. Child Adolesc. Psychiatry 31:455-461.
  • Handen, B. L., J. Janosky, S. McAuliffe, A. M. Breaux, and H. Feldman. 1994. Prediction of response to methylphenidate among children with ADHD and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry 33:1185-1193.
  • Handen, B. L., S. McAuliffe, and L. Caro-Martinez. 1996. Learning effects of methylphenidate in children with mental retardation. J. Dev. Phys. Disabil. 8:335-346.
  • Handen, B. L., C. R. Johnson, and M. Lubetsky. 2000. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J. Autism Dev. Disord. 30:245-255.
  • Harpey, J. P. 1982. Treatment of fragile X [letter]. Pediatrics 69:670.
  • Hartman, N., R. Kramer, W. T. Brown, and R. B. Devereux. 1982. Panic disorder in patients with mitral valve prolapse. Am. J. Psychiatry 139:669-670.
  • Hecht, F., and T. W. Glover. 1983. Antibiotics containing trimethoprim and the fragile X chromosome [letter]. N. Engl. J. Med. 308:285.
  • Hellings, J. A. 1999. Psychopharmacology of mood disorders in persons with mental retardation and autism. Ment. Retard. Dev. Disabil. Res. Rev. 5:270-278.
  • Hellings, J. A., L. A. Kelley, W. F. Gabrielli, E. Kilgore, and P. Shah. 1996. Sertraline response in adults with mental retardation and autistic disorder. J. Clin. Psychiatry 57:333-336.
  • Hewlett, W. A., S. Vinogradov, and W. S. Agras. 1992. Clomipramine, clonacepan and clonidine treatment of obsessive/compulsive disorder. J. Clin. Psychopharmacol. 12:420-426.
  • Hilton, D. K., C. A. Martin, W. M. Heffron, D. D. Hall, and G. L. Johnson. 1991. Imipramine treatment of ADHD in a fragile X child. J. Am. Acad. Child Adolesc. Psychiatry 30:831-834.
  • Hoge, S. K., and J. Biederman. 1986. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J. Clin. Psychiatry 47:478-479.
  • Hollander, E., A. Kaplan, C. Cartwright, and D. Reichman. 2000. Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: An open retrospective clinical report. J. Child Neurol. 15:132-135.
  • Honey, G. D., E. T. Bullmore, W. Soni, M. Varatheesan, S. C. Williams, and T. Sharma. 1999. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia [see comments]. Proc. Natl. Acad. Sci. USA 96:13432-13437.
  • Horrigan, J. P., and L. J. Barnhill. 1997. Risperidone and explosive aggressive autism. J. Autism Dev. Disord. 27:313-323.
  • Hunt, R. D. 1987. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: An open pilot study. Psychopharmacol. Bull. 23:111-114.
  • Hunt, R. D., R. B. Mindera, and D. J. Cohen. 1985. Clonidine benefits children with attentional deficit disorder and hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry 24:617-629.
  • Hunt, R. D., A. F. T. Arnsten, and M. D. Asbell. 1995. An open trial of guanfacine in treatment of attention deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 34:50-54.
  • Hunter, R., J. Barnes, H. F. Oakeley, and D. M. Matthews. 1970. Toxocity of folic acid given in pharmacological doses to healthy volunteers. Lancet 1:61-63.
     

This article is not intended to give medical advice for individual cases.  Any change in medical treatment should be done in consultation with appropriate medical personnel. This article is written for medical professionals.  Some of the terms will be unfamiliar to those who are not trained in medical fields.

*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002.  It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in the book which are not included as part of this website.

The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling 1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.

Medical Follow-up   Pharmacotherapy   Future Prospects
Outline   Medications   Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
 
back to homehow to navigatesite map creditsprivacycontact usdisclaimer

© copyright 1998-2008 NFXF
 
Medication can be important in the treatment of fragile X related behavior problems
TELL A FRIEND